Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LY 156735

Next Previous
X
Search
Drug Profile

LY 156735

Alternative Names: LY156,735; PD 6735; TIK-301

Latest Information Update: 26 Mar 2009

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Tikvah Therapeutics
  • Class Sleep disorder therapies; Small molecules; Tryptamines
  • Mechanism of Action Melatonin receptor agonists; Serotonin 2C receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Sleep disorders

Most Recent Events

  • 25 Nov 2005 Data presented at the 18th Annual Congress of the European College of Neuropsychopharmacology (ECNP-2005) have been added to the adverse events and Anxiety disorders therapeutic trials sections
  • 28 May 2004 LY 156735 has received orphan drug status for the treatment of circadian sleep disorders in totally blind individuals in the US
  • 24 May 2004 Data from a media release have been added to the Anxiety disorders therapeutic trials section

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top